RGL-305+ Lymphoma + Exploratory Clinical Study — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

RGL-305+ Lymphoma + Exploratory Clinical Study — Stella

Recruiting

Back to Lymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD) trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality

Key details

Sponsor

Fudan University

Enrollment target

~12 participants

Started

April 2025

Primary completion

March 2028

Age range

18 Years – 75 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov